Linical Co., Ltd. (JP:2183)
:2183
Want to see JP:2183 full AI Analyst Report?
2183 Stock Chart & Stats
¥293.00
-¥1.00(-0.28%)
At close: 4:00 PM EST
¥293.00
-¥1.00(-0.28%)
Day’s Range― - ―
52-Week Range¥236.00 - ¥363.00
Previous CloseN/A
Volume36.50K
Average Volume (3M)14.99K
Market Cap
¥5.33B
Enterprise Value¥2.53B
Total Cash (Recent Filing)¥5.53B
Total Debt (Recent Filing)¥2.22B
Price to Earnings (P/E)―
Beta0.64
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield5.44%
Share Statistics
EPS (TTM)-28.06
Shares Outstanding24,740,000
10 Day Avg. Volume18,600
30 Day Avg. Volume14,993
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)1.00
Price to Sales (P/S)0.69
P/FCF Ratio12.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)29.7
Revenue Forecast (FY)¥13.00B
Bulls Say, Bears Say
Bulls Say
End-to-end CRO Service MixLinical's broad, end-to-end CRO service set creates durable revenue continuity and stronger client stickiness: sponsors prefer single vendors for multi-service trials, reducing sales churn, enabling upsells, and supporting steady contract pipelines over multiple quarters.
Moderate Leverage And LiquidityModerate leverage and a negative net debt position give Linical financial flexibility to support multi-site trials, absorb timing mismatches in milestone billing, and invest selectively in capacity or technology without immediate pressure for external financing.
Positive Operating Cash GenerationPositive operating cash flow supports working capital for ongoing studies and reduces reliance on external liquidity. Even with declining FCF, consistent cash generation underpins day-to-day operations and funds client delivery over coming quarters.
Bears Say
Revenue Decline TrendA material year-over-year revenue decline reduces economies of scale and utilization of professional staff in a people-driven CRO model. Persisting revenue weakness can erode backlog, limit reinvestment in capabilities, and increase per-project fixed-cost exposure over the next several quarters.
Negative Net Income And Margin DeteriorationNegative net income and worsening margins constrain the firm's ability to fund growth initiatives, retain specialized staff, and price competitively. Margin erosion diminishes internal funding for technology and quality investments central to long-term CRO competitiveness.
Declining Free Cash Flow TrendA falling free cash flow trend reduces the buffer for lumpy milestone payments and clinical trial timing variability. Continued decline could force prioritization of projects, slow capacity expansion, or push the company toward external financing within a multi-month horizon.
Linical Co., Ltd. News
2183 FAQ
What was Linical Co., Ltd.’s price range in the past 12 months?
Linical Co., Ltd. lowest stock price was ¥236.00 and its highest was ¥363.00 in the past 12 months.
What is Linical Co., Ltd.’s market cap?
Linical Co., Ltd.’s market cap is ¥5.33B.
When is Linical Co., Ltd.’s upcoming earnings report date?
Linical Co., Ltd.’s upcoming earnings report date is Aug 13, 2026 which is in 88 days.
How were Linical Co., Ltd.’s earnings last quarter?
Linical Co., Ltd. released its earnings results on May 15, 2026. The company reported -¥78.737 earnings per share for the quarter, missing the consensus estimate of N/A by -¥78.737.
Is Linical Co., Ltd. overvalued?
According to Wall Street analysts Linical Co., Ltd.’s price is currently Overvalued.
Does Linical Co., Ltd. pay dividends?
Linical Co., Ltd. pays a Annually dividend of ¥16 which represents an annual dividend yield of 5.44%. See more information on Linical Co., Ltd. dividends here
What is Linical Co., Ltd.’s EPS estimate?
Linical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Linical Co., Ltd. have?
Linical Co., Ltd. has 24,740,000 shares outstanding.
What happened to Linical Co., Ltd.’s price movement after its last earnings report?
Linical Co., Ltd. reported an EPS of -¥78.737 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.667%.
Which hedge fund is a major shareholder of Linical Co., Ltd.?
Currently, no hedge funds are holding shares in JP:2183
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Linical Co., Ltd.
Linical Co., Ltd. provides drug development services primarily in the areas of oncology and central nervous system to pharmaceutical companies worldwide. The company offers drug development consulting services, such as market analysis of products in development, regulatory affairs consultation support, and licensing support. It also provides clinical research and development, and contract medical affairs services, including front-end services comprising project management, monitoring, quality control, vendor management, auditing, and clinical research secretariat; and back-end services, which include data management, bio statistical analysis, medical writing, pharmacovigilance, and medical management. The company was incorporated in 2005 and is headquartered in Osaka, Japan.
Technical Analysis
Trans Genic Inc.
―
MEDINET Co., Ltd.
―
TMS Co., Ltd.
―
Takara Bio Inc.
―
ReproCELL Inc.
―